Pluriformity of inflammation in multiple sclerosis shown by ultra-small iron oxide particle enhancement.

Gadolinium-DTPA (Gd-DTPA) is routinely used as a marker for inflammation in MRI to visualize breakdown of the blood-brain barrier (BBB) in multiple sclerosis. Recent data suggest that ultra-small superparamagnetic particles of iron oxide (USPIO) can be used to visualize cellular infiltration, another aspect of inflammation. This project aimed to compare the novel USPIO particle SHU555C to the longitudinal pattern of Gd-DTPA enhancement in multiple sclerosis. Nineteen relapsing-remitting patients were screened monthly using Gd-enhanced MRI. In case of new enhancing lesions, USPIO were injected and 24 h later, MRI was performed and blood was collected to confirm USPIO loading of circulating monocytes. Lesion development was monitored by 3 monthly Gd-DTPA-enhanced scans and a final scan 7-11 months after injection. USPIO-enhancement was observed as hyperintensity on T1-weighted images, whereas no signal changes were observed on T2-weighted-gradient-echo images. In 14 patients with disease activity, 188 USPIO-positive lesions were seen, 144 of which were Gd-negative. By contrast, there were a total of 59 Gd-positive lesions, 15 of which were USPIO negative. Three patterns of USPIO-enhancement were seen: (i) focal enhancement; (ii) ring-like enhancement and (iii) return to isointensity of a previously hypointense lesion. The latter pattern was most frequently observed for lesions that turned out to be transiently hypointense on follow-up scans, and ring-enhancing lesions were less likely to evolve into black holes at follow-up than lesions without ring-like USPIO-enhancement; we speculate this to be associated with repair. In 4% of the USPIO-positive/Gd negative lesions, USPIO-enhancement preceded Gd-enhancement by 1 month. USPIO-enhancement remained visible for up to 3 months in 1.5% of all USPIO-positive lesions. In 29% of the lesions enhancing with both contrast agents, USPIO-enhancement persisted whereas Gd-enhancement had already resolved. In conclusion, the new nano-particle SHU555C provides complementary information to Gd-enhanced MRI, probably related to monocyte infiltration. The use of USPIO-enhanced MRI is likely to lead to more insight in the pluriformity of inflammation in multiple sclerosis.

[1]  E. Neuwelt,et al.  An exploratory study of ferumoxtran-10 nanoparticles as a blood-brain barrier imaging agent targeting phagocytic cells in CNS inflammatory lesions. , 2005, AJNR. American journal of neuroradiology.

[2]  Philippe Robert,et al.  Recent advances in iron oxide nanocrystal technology for medical imaging. , 2006, Advanced drug delivery reviews.

[3]  E. Neuwelt,et al.  Imaging of iron oxide nanoparticles by MR and light microscopy in patients with malignant brain tumours , 2004, Neuropathology and applied neurobiology.

[4]  Frederik Barkhof,et al.  Remyelinated lesions in multiple sclerosis: magnetic resonance image appearance. , 2003, Archives of neurology.

[5]  H. D. de Vries,et al.  Comparison of SPIO and USPIO for in vitro labeling of human monocytes: MR detection and cell function. , 2007, Radiology.

[6]  Bruno Brochet,et al.  Early macrophage MRI of inflammatory lesions predicts lesion severity and disease development in relapsing EAE , 2006, NeuroImage.

[7]  K. Nicolay,et al.  Blood-brain barrier permeability and monocyte infiltration in experimental allergic encephalomyelitis: a quantitative MRI study. , 2004, Brain : a journal of neurology.

[8]  R. Hohlfeld.  Does inflammation stimulate remyelination? , 2007, Journal of Neurology.

[9]  H I Goldberg,et al.  Multiple sclerosis: serial study of gadolinium-enhanced MR imaging. , 1988, Radiology.

[10]  P. Trouillas,et al.  Inflammatory Response After Ischemic Stroke , 2007 .

[11]  À. Rovira,et al.  Evolution of multiple sclerosis lesions on serial contrast-enhanced T1-weighted and magnetization-transfer MR images. , 1999, AJNR. American journal of neuroradiology.

[12]  M. E. Kooi,et al.  Accumulation of Ultrasmall Superparamagnetic Particles of Iron Oxide in Human Atherosclerotic Plaques Can Be Detected by In Vivo Magnetic Resonance Imaging , 2003, Circulation.

[13]  C. Good,et al.  A modified protocol to improve the detection of enhancing brain and spinal cord leasions in multiple sclerosis , 2001, Journal of Neurology.

[14]  Ernst J. Rummeny,et al.  Capacity of human monocytes to phagocytose approved iron oxide MR contrast agents in vitro , 2004, European Radiology.

[15]  A. Bartsch,et al.  Is the disruption of the blood-brain barrier a prerequisite for cellular infiltration in autoimmune encephalitis? , 2005, Brain : a journal of neurology.

[16]  H. Tobi,et al.  Correlating MRI and clinical disease activity in multiple sclerosis , 1995, Neurology.

[17]  M. Rausch,et al.  Predictability of FTY720 efficacy in experimental autoimmune encephalomyelitis by in vivo macrophage tracking: Clinical implications for ultrasmall superparamagnetic iron oxide‐enhanced magnetic resonance imaging , 2004, Journal of magnetic resonance imaging : JMRI.

[18]  F. Barkhof,et al.  Blood–brain barrier alterations in both focal and diffuse abnormalities on postmortem MRI in multiple sclerosis , 2005, Neurobiology of Disease.

[19]  Andreas Saleh,et al.  Imaging Inflammation in Acute Brain Ischemia , 2007, Stroke.

[20]  Andreas Saleh,et al.  In vivo MRI of brain in ̄ ammation in human ischaemic stroke , 2004 .

[21]  R. Musters,et al.  Lipoic Acid Affects Cellular Migration into the Central Nervous System and Stabilizes Blood-Brain Barrier Integrity1 , 2006, The Journal of Immunology.

[22]  C Delalande,et al.  Comparison of ultrasmall particles of iron oxide (USPIO)-enhanced T2-weighted, conventional T2-weighted, and gadolinium-enhanced T1-weighted MR images in rats with experimental autoimmune encephalomyelitis. , 1999, AJNR. American journal of neuroradiology.

[23]  J. Kurtzke.  Rating neurologic impairment in multiple sclerosis , 1983, Neurology.

[24]  P. Trouillas,et al.  Inflammatory Response After Ischemic Stroke: A USPIO-Enhanced MRI Study in Patients , 2007, Stroke.

[25]  B Quesson,et al.  In vivo macrophage activity imaging in the central nervous system detected by magnetic resonance , 1999, Magnetic resonance in medicine.

[26]  J. Bulte,et al.  Study of relapsing remitting experimental allergic encephalomyelitis SJL mouse model using MION‐46L enhanced in vivo MRI: Early histopathological correlation , 1998, Journal of Neuroscience Research.

[27]  J. Caillé,et al.  MR imaging of relapsing multiple sclerosis patients using ultra-small-particle iron oxide and compared with gadolinium. , 2006, AJNR. American journal of neuroradiology.

[28]  F. Barkhof,et al.  Patterns of lesion development in multiple sclerosis: longitudinal observations with T1-weighted spin-echo and magnetization transfer MR. , 1998, AJNR. American journal of neuroradiology.

[29]  M. Rausch,et al.  MRI‐based monitoring of inflammation and tissue damage in acute and chronic relapsing EAE , 2003, Magnetic resonance in medicine.

[30]  M. Wendland,et al.  T1 and T2 relaxivity of intracellular and extracellular USPIO at 1.5T and 3T clinical MR scanning , 2006, European Radiology.